EA201291463A1 - Составы для инфузии лантибиотиков типа b - Google Patents

Составы для инфузии лантибиотиков типа b

Info

Publication number
EA201291463A1
EA201291463A1 EA201291463A EA201291463A EA201291463A1 EA 201291463 A1 EA201291463 A1 EA 201291463A1 EA 201291463 A EA201291463 A EA 201291463A EA 201291463 A EA201291463 A EA 201291463A EA 201291463 A1 EA201291463 A1 EA 201291463A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lantibiotic
infantion
compositions
type
infusion
Prior art date
Application number
EA201291463A
Other languages
English (en)
Other versions
EA024344B1 (ru
Inventor
Энтони Николас Апплеярд
Сьёрд Николаас Вадман
Original Assignee
Новакта Биосистемс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новакта Биосистемс Лимитед filed Critical Новакта Биосистемс Лимитед
Publication of EA201291463A1 publication Critical patent/EA201291463A1/ru
Publication of EA024344B1 publication Critical patent/EA024344B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложен жидкий коллоидный фармацевтический состав лантибиотика типа В для инфузии или прямой инъекции, содержащий лантибиотик типа В или его соль, изотонический водный раствор, содержащий сахарный спирт, такой как глицерин и/или сахарид, и, возможно, буфер, при этом указанный готовый состав для инфузии или прямой инъекции не содержит видимых частиц.
EA201291463A 2010-08-11 2011-08-09 Составы для инфузии лантибиотиков типа b EA024344B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1013513.5A GB201013513D0 (en) 2010-08-11 2010-08-11 Formulations
PCT/GB2011/001191 WO2012020219A2 (en) 2010-08-11 2011-08-09 Formulations for infusion of type b lantibiotics

Publications (2)

Publication Number Publication Date
EA201291463A1 true EA201291463A1 (ru) 2013-07-30
EA024344B1 EA024344B1 (ru) 2016-09-30

Family

ID=42931511

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291463A EA024344B1 (ru) 2010-08-11 2011-08-09 Составы для инфузии лантибиотиков типа b

Country Status (9)

Country Link
US (1) US9192569B2 (ru)
EP (1) EP2603204A2 (ru)
JP (1) JP5865374B2 (ru)
CN (1) CN103108628B (ru)
CA (1) CA2807206A1 (ru)
EA (1) EA024344B1 (ru)
GB (1) GB201013513D0 (ru)
MX (1) MX2013001470A (ru)
WO (1) WO2012020219A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563144B (zh) 2016-06-01 2023-03-28 雅斯娜 化合物
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
CN109620979B (zh) * 2018-12-29 2020-09-01 福建师范大学 低离子休克提高氨基糖苷类抗生素杀灭持留菌效率的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1013513A (en) 1963-03-25 1965-12-15 Watney Combe Reid & Co Ltd Improvements in and relating to hopping beer
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (ru) 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
DE69433357T2 (de) 1994-09-12 2004-09-09 Aventis Pharma Deutschland Gmbh Rekombinantes Mersacidin und Verfahren zu seiner Herstellung
NZ311535A (en) 1995-06-23 2001-05-25 Ambi Inc A method for the control of antibiotic-resistant gram positive bacteria and treatment of infection
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5985823A (en) 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
DE19745583A1 (de) 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
CA2413702A1 (en) 2000-06-28 2002-01-03 Teva Pharmaceuticals Industries Ltd. Carvedilol
CA2413330A1 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
AU2003275129A1 (en) 2002-10-10 2004-05-04 Molichem Medicines, Inc. Nucleic acids encoding duramycin
MXPA05004121A (es) * 2002-10-18 2006-02-17 Molichem Medicines Inc Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
BRPI0412591A (pt) 2003-07-18 2006-09-19 Vicuron Pharm Inc antibiótico 107891, seus fatores a1 e a2, sais e composições farmaceuticamente aceitáveis e uso destes
US20050271650A1 (en) 2004-02-17 2005-12-08 Cellmatrix, Inc. Method and composition for angiogenesis inhibition
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
JP2009509519A (ja) 2005-09-27 2009-03-12 ノヴァクタ バイオシステムズ リミティッド ランチビオティックメルサシジンの変種およびそれらの使用
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
KR101170283B1 (ko) 2006-10-27 2012-07-31 화이자 프로덕츠 인코포레이티드 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법
CA2690267A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
BRPI0822946A2 (pt) 2008-11-24 2015-06-23 Sentinella Pharmaceuticals Inc Sentinella Derivado de carboxiamida, processo para preparação de derivado de carboxiamida, composição farmacêutica e uso do derivado de carboxiamida
DK2387580T3 (da) 2009-01-14 2014-10-13 Novacta Biosystems Ltd Deoxyactagardinderivater
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
CN102388060B (zh) 2009-02-04 2014-09-10 诺瓦克塔生物系统有限公司 阿肽加定衍生物
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
JP5852966B2 (ja) 2010-02-02 2016-02-03 ノヴァクタ バイオシステムズ リミティッド ランチビオティックの塩
CA2804697A1 (en) 2010-07-14 2012-01-19 Novacta Biosystems Limited Formulation comprising a type b lantibiotic

Also Published As

Publication number Publication date
WO2012020219A3 (en) 2012-04-05
GB201013513D0 (en) 2010-09-22
WO2012020219A2 (en) 2012-02-16
US9192569B2 (en) 2015-11-24
EP2603204A2 (en) 2013-06-19
US20130137630A1 (en) 2013-05-30
CN103108628A (zh) 2013-05-15
EA024344B1 (ru) 2016-09-30
CA2807206A1 (en) 2012-02-16
CN103108628B (zh) 2015-08-05
JP2013533304A (ja) 2013-08-22
JP5865374B2 (ja) 2016-02-17
MX2013001470A (es) 2013-05-14

Similar Documents

Publication Publication Date Title
PH12014502778A1 (en) Antibody formulation
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201201659A1 (ru) Водная композиция, содержащая бромгексин
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
MY156188A (en) Long - acting formulations of insulins
PH12015500850A1 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
CL2014001345A1 (es) Metodos de tratamiento usando un anticuerpo contra interferon gamma; usos composicion farmaceutica que contiene un anticuerpo contra interferon gamma.
BR112013026883A2 (pt) Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
WO2014199352A3 (en) Lipid-based platinum-n-heterocyclic carbene compounds and nanoparticles
AR098168A1 (es) Formulación estable de insulina glulisina
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
PE20150190A1 (es) Formulacion farmaceutica
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
EA201391729A1 (ru) Состав, содержащий антитело
EA201390467A1 (ru) Композиции антител и способы применения
TR201910572T4 (tr) Anti-cd26 antikorları ve bunların kullanımları.
PH12015500704A1 (en) Pharmaceutical composition comprising rebamipide
EA201291463A1 (ru) Составы для инфузии лантибиотиков типа b
MX2014009660A (es) Formulacion de anticuerpo anti-selectina p.
MX2014013083A (es) Composicion farmaceutica inyectable de dexketoprofeno y tramadol.
EA201590452A1 (ru) СОЛИ СОЕДИНЕНИЯ БЕНЗОТИАЗОЛОНА В КАЧЕСТВЕ АГОНИСТОВ β-2-АДРЕНОРЕЦЕПТОРОВ
RU2011127039A (ru) Алкогольный напиток

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU